Response to comments on "PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational study".
APA
Yang CY, Shih JY (2026). Response to comments on "PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational study".. Journal of the Formosan Medical Association = Taiwan yi zhi, 125(4), 488-489. https://doi.org/10.1016/j.jfma.2025.04.028
MLA
Yang CY, et al.. "Response to comments on "PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational study".." Journal of the Formosan Medical Association = Taiwan yi zhi, vol. 125, no. 4, 2026, pp. 488-489.
PMID
40307152
같은 제1저자의 인용 많은 논문 (5)
- PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational study.
- Cynaropicrin: A promising sesquiterpene lactone with multifaceted therapeutic potential for various diseases.
- Risk of death from bladder cancer in relation to long-term exposure to fine particulate air pollution in Taiwan.
- Evaluation of Collagen Dermal Filler with Lidocaine for the Correction of Nasolabial Folds: A Randomized, Double-Blind, Multicenter Clinical Trial.
- Hepatopulmonary metastases from papillary thyroid microcarcinoma: A case report.